#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Nucleus	_
1-2	8-17	Accumbens	_
1-3	18-28	Functional	_
1-4	29-41	Connectivity	_
1-5	42-44	at	_
1-6	45-48	Age	_
1-7	49-51	20	_
1-8	52-54	is	_
1-9	55-65	Associated	_
1-10	66-70	with	_
1-11	71-81	Trajectory	_
1-12	82-84	of	_
1-13	85-95	Adolescent	_
1-14	96-104	Cannabis	_
1-15	105-108	Use	_
1-16	109-112	and	_
1-17	113-121	Predicts	_
1-18	122-134	Psychosocial	_
1-19	135-146	Functioning	_
1-20	147-149	in	_
1-21	150-155	Young	_
1-22	156-165	Adulthood	_
1-23	166-170	Aims	_
1-24	171-172	1	_
1-25	173-174	)	_
1-26	175-177	To	_
1-27	178-186	identify	_
1-28	187-199	trajectories	_
1-29	200-202	of	_
1-30	203-211	cannabis	_
1-31	212-215	use	_
1-32	216-222	across	_
1-33	223-234	adolescence	_
1-34	235-236	,	_
1-35	237-238	2	_
1-36	239-240	)	_
1-37	241-243	to	_
1-38	244-251	measure	_
1-39	252-255	the	_
1-40	256-265	influence	_
1-41	266-268	of	_
1-42	269-277	cannabis	_
1-43	278-281	use	_
1-44	282-297	characteristics	_
1-45	298-300	on	_
1-46	301-311	functional	_
1-47	312-324	connectivity	_
1-48	325-327	of	_
1-49	328-331	the	_
1-50	332-339	nucleus	_
1-51	340-349	accumbens	_
1-52	350-351	(	_
1-53	352-356	NAcc	_
1-54	357-358	)	_
1-55	359-360	,	_
1-56	361-364	and	_
1-57	365-366	3	_
1-58	367-368	)	_
1-59	369-371	to	_
1-60	372-378	assess	_
1-61	379-386	whether	_
1-62	387-395	patterns	_
1-63	396-398	of	_
1-64	399-409	functional	_
1-65	410-422	connectivity	_
1-66	423-430	related	_
1-67	431-433	to	_
1-68	434-442	cannabis	_
1-69	443-446	use	_
1-70	447-450	are	_
1-71	451-461	associated	_
1-72	462-466	with	_
1-73	467-479	psychosocial	_
1-74	480-491	functioning	_
1-75	492-493	2	_
1-76	494-499	years	_
1-77	500-505	later	_
1-78	506-507	.	_

2-1	508-514	Design	_
2-2	515-518	The	_
2-3	519-523	Pitt	_
2-4	524-530	Mother	_
2-5	531-532	&	http://maven.renci.org/NeuroBridge/neurobridge#ChildrensMemoryScale
2-6	533-538	Child	http://maven.renci.org/NeuroBridge/neurobridge#ChildrensMemoryScale
2-7	539-546	Project	_
2-8	547-548	(	_
2-9	549-553	PMCP	_
2-10	554-555	)	_
2-11	556-558	is	_
2-12	559-560	a	_
2-13	561-572	prospective	_
2-14	573-574	,	_
2-15	575-587	longitudinal	_
2-16	588-593	study	_
2-17	594-596	of	_
2-18	597-601	male	_
2-19	602-607	youth	_
2-20	608-610	at	_
2-21	611-615	high	_
2-22	616-620	risk	_
2-23	621-624	for	_
2-24	625-640	psychopathology	_
2-25	641-646	based	_
2-26	647-649	on	_
2-27	650-656	family	_
2-28	657-663	income	_
2-29	664-667	and	_
2-30	668-674	gender	_
2-31	675-676	.	_

3-1	677-684	Setting	_
3-2	685-697	Participants	_
3-3	698-702	were	_
3-4	703-712	recruited	_
3-5	713-720	between	_
3-6	721-724	age	_
3-7	725-729	6–17	_
3-8	730-736	months	_
3-9	737-741	from	_
3-10	742-745	the	_
3-11	746-751	Women	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
3-12	752-753	,	_
3-13	754-761	Infants	http://maven.renci.org/NeuroBridge/neurobridge#PainFinding
3-14	762-763	,	_
3-15	764-767	and	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-16	768-776	Children	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-17	777-788	Nutritional	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-18	789-799	Supplement	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
3-19	800-807	program	_
3-20	808-809	(	_
3-21	810-813	WIC	_
3-22	814-815	)	_
3-23	816-818	in	_
3-24	819-822	the	_
3-25	823-833	Pittsburgh	_
3-26	834-835	,	_
3-27	836-848	Pennsylvania	_
3-28	849-853	area	_
3-29	854-855	.	_

4-1	856-868	Participants	_
4-2	869-874	N=158	_
4-3	875-879	PMCP	_
4-4	880-885	young	_
4-5	886-889	men	_
4-6	890-901	contributed	_
4-7	902-906	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-8	907-910	and	_
4-9	911-920	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
4-10	921-924	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
4-11	925-929	data	_
4-12	930-932	at	_
4-13	933-936	age	_
4-14	937-939	20	_
4-15	940-941	.	_

5-1	942-954	Measurements	_
5-2	955-961	Latent	_
5-3	962-967	class	_
5-4	968-974	growth	_
5-5	975-983	analysis	_
5-6	984-987	was	_
5-7	988-992	used	_
5-8	993-995	to	_
5-9	996-1005	determine	_
5-10	1006-1018	trajectories	_
5-11	1019-1021	of	_
5-12	1022-1030	cannabis	_
5-13	1031-1034	use	_
5-14	1035-1044	frequency	_
5-15	1045-1049	from	_
5-16	1050-1053	age	_
5-17	1054-1059	14–19	_
5-18	1060-1061	.	_

6-1	1062-1081	Psychophysiological	_
6-2	1082-1093	interaction	_
6-3	1094-1095	(	_
6-4	1096-1099	PPI	_
6-5	1100-1101	)	_
6-6	1102-1110	analysis	_
6-7	1111-1114	was	_
6-8	1115-1119	used	_
6-9	1120-1122	to	_
6-10	1123-1130	measure	_
6-11	1131-1141	functional	_
6-12	1142-1154	connectivity	_
6-13	1155-1162	between	_
6-14	1163-1166	the	_
6-15	1167-1171	NAcc	_
6-16	1172-1175	and	_
6-17	1176-1186	prefrontal	_
6-18	1187-1193	cortex	_
6-19	1194-1195	(	_
6-20	1196-1199	PFC	_
6-21	1200-1201	)	_
6-22	1202-1203	.	_

7-1	1204-1214	Adolescent	_
7-2	1215-1223	cannabis	_
7-3	1224-1227	use	_
7-4	1228-1238	trajectory	_
7-5	1239-1240	,	_
7-6	1241-1247	recent	_
7-7	1248-1257	frequency	_
7-8	1258-1260	of	_
7-9	1261-1264	use	_
7-10	1265-1266	,	_
7-11	1267-1270	and	_
7-12	1271-1274	age	_
7-13	1275-1277	of	_
7-14	1278-1288	initiation	_
7-15	1289-1293	were	_
7-16	1294-1304	considered	_
7-17	1305-1307	as	_
7-18	1308-1321	developmental	_
7-19	1322-1329	factors	_
7-20	1330-1331	.	_

8-1	1332-1334	We	_
8-2	1335-1339	also	_
8-3	1340-1346	tested	_
8-4	1347-1354	whether	_
8-5	1355-1365	functional	_
8-6	1366-1378	connectivity	_
8-7	1379-1382	was	_
8-8	1383-1393	associated	_
8-9	1394-1398	with	_
8-10	1399-1409	depressive	_
8-11	1410-1418	symptoms	_
8-12	1419-1420	,	_
8-13	1421-1430	anhedonia	_
8-14	1431-1432	,	_
8-15	1433-1436	and	_
8-16	1437-1448	educational	_
8-17	1449-1459	attainment	_
8-18	1460-1462	at	_
8-19	1463-1466	age	_
8-20	1467-1469	22	_
8-21	1470-1471	.	_

9-1	1472-1480	Findings	_
9-2	1481-1483	We	_
9-3	1484-1494	identified	_
9-4	1495-1500	three	_
9-5	1501-1509	distinct	_
9-6	1510-1522	trajectories	_
9-7	1523-1525	of	_
9-8	1526-1536	adolescent	_
9-9	1537-1545	cannabis	_
9-10	1546-1549	use	_
9-11	1550-1551	,	_
9-12	1552-1565	characterized	_
9-13	1566-1568	by	_
9-14	1569-1575	stable	_
9-15	1576-1580	high	_
9-16	1581-1582	,	_
9-17	1583-1593	escalating	_
9-18	1594-1595	,	_
9-19	1596-1598	or	_
9-20	1599-1605	stable	_
9-21	1606-1609	low	_
9-22	1610-1613	use	_
9-23	1614-1615	.	_

10-1	1616-1624	Cannabis	_
10-2	1625-1628	use	_
10-3	1629-1639	trajectory	_
10-4	1640-1645	group	_
10-5	1646-1649	had	_
10-6	1650-1651	a	_
10-7	1652-1663	significant	_
10-8	1664-1670	effect	_
10-9	1671-1673	on	_
10-10	1674-1678	NAcc	_
10-11	1679-1689	functional	_
10-12	1690-1702	connectivity	_
10-13	1703-1705	to	_
10-14	1706-1709	the	_
10-15	1710-1716	medial	_
10-16	1717-1720	PFC	_
10-17	1721-1722	(	_
10-18	1723-1730	F=11.32	_
10-19	1731-1732	,	_
10-20	1733-1739	Z=4.04	_
10-21	1740-1741	,	_
10-22	1742-1756	pFWE-corr=.000	_
10-23	1757-1758	)	_
10-24	1759-1760	.	_

11-1	1761-1764	The	_
11-2	1765-1775	escalating	_
11-3	1776-1786	trajectory	_
11-4	1787-1792	group	_
11-5	1793-1802	displayed	_
11-6	1803-1804	a	_
11-7	1805-1812	pattern	_
11-8	1813-1815	of	_
11-9	1816-1824	negative	_
11-10	1825-1834	NAcc-mPFC	_
11-11	1835-1847	connectivity	_
11-12	1848-1852	that	_
11-13	1853-1856	was	_
11-14	1857-1863	linked	_
11-15	1864-1866	to	_
11-16	1867-1873	higher	_
11-17	1874-1880	levels	_
11-18	1881-1883	of	_
11-19	1884-1894	depressive	_
11-20	1895-1903	symptoms	_
11-21	1904-1905	(	_
11-22	1906-1912	r=−.17	_
11-23	1913-1914	,	_
11-24	1915-1921	p=.041	_
11-25	1922-1923	)	_
11-26	1924-1925	,	_
11-27	1926-1935	anhedonia	_
11-28	1936-1937	(	_
11-29	1938-1944	r=−.19	_
11-30	1945-1946	,	_
11-31	1947-1953	p=.028	_
11-32	1954-1955	)	_
11-33	1956-1957	,	_
11-34	1958-1961	and	_
11-35	1962-1967	lower	_
11-36	1968-1979	educational	_
11-37	1980-1990	attainment	_
11-38	1991-1992	(	_
11-39	1993-2000	t=−2.77	_
11-40	2001-2002	,	_
11-41	2003-2009	p=.006	_
11-42	2010-2011	)	_
11-43	2012-2014	at	_
11-44	2015-2018	age	_
11-45	2019-2021	22	_
11-46	2022-2023	.	_

12-1	2024-2035	Conclusions	_
12-2	2036-2043	Pattern	_
12-3	2044-2046	of	_
12-4	2047-2055	cannabis	_
12-5	2056-2059	use	_
12-6	2060-2069	frequency	_
12-7	2070-2076	across	_
12-8	2077-2088	adolescence	_
12-9	2089-2091	in	_
12-10	2092-2094	US	_
12-11	2095-2100	youth	_
12-12	2101-2106	could	_
12-13	2107-2111	have	_
12-14	2112-2124	consequences	_
12-15	2125-2128	for	_
12-16	2129-2133	mood	_
12-17	2134-2142	symptoms	_
12-18	2143-2146	and	_
12-19	2147-2158	educational	_
12-20	2159-2169	attainment	_
12-21	2170-2172	in	_
12-22	2173-2178	early	_
12-23	2179-2188	adulthood	_
12-24	2189-2192	via	_
12-25	2193-2200	altered	_
12-26	2201-2209	function	_
12-27	2210-2212	in	_
12-28	2213-2219	neural	_
12-29	2220-2226	reward	_
12-30	2227-2236	circuitry	_
12-31	2237-2238	.	_

13-1	2239-2246	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
13-2	2247-2253	Design	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
13-3	2254-2257	The	_
13-4	2258-2262	Pitt	http://maven.renci.org/NeuroBridge/neurobridge#ChildrensMemoryScale
13-5	2263-2269	Mother	http://maven.renci.org/NeuroBridge/neurobridge#ChildrensMemoryScale
13-6	2270-2271	&	http://maven.renci.org/NeuroBridge/neurobridge#ChildrensMemoryScale
13-7	2272-2277	Child	http://maven.renci.org/NeuroBridge/neurobridge#ChildrensMemoryScale
13-8	2278-2285	Project	_
13-9	2286-2287	(	_
13-10	2288-2292	PMCP	_
13-11	2293-2294	)	_
13-12	2295-2297	is	_
13-13	2298-2299	a	_
13-14	2300-2311	prospective	_
13-15	2312-2313	,	_
13-16	2314-2326	longitudinal	_
13-17	2327-2332	study	_
13-18	2333-2335	of	_
13-19	2336-2340	risk	_
13-20	2341-2344	and	_
13-21	2345-2355	resiliency	_
13-22	2356-2361	among	_
13-23	2362-2372	low-income	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
13-24	2373-2377	male	_
13-25	2378-2390	participants	_
13-26	2391-2400	recruited	_
13-27	2401-2405	from	_
13-28	2406-2409	the	_
13-29	2410-2420	Pittsburgh	_
13-30	2421-2422	,	_
13-31	2423-2435	Pennsylvania	_
13-32	2436-2440	area	_
13-33	2441-2442	.	_

14-1	2443-2447	This	_
14-2	2448-2453	study	_
14-3	2454-2457	was	_
14-4	2458-2467	initiated	_
14-5	2468-2470	in	_
14-6	2471-2475	1991	_
14-7	2476-2479	and	_
14-8	2480-2481	a	_
14-9	2482-2487	total	_
14-10	2488-2490	of	_
14-11	2491-2496	N=310	_
14-12	2497-2505	families	_
14-13	2506-2510	were	_
14-14	2511-2520	recruited	_
14-15	2521-2525	from	_
14-16	2526-2531	Women	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
14-17	2532-2533	,	_
14-18	2534-2540	Infant	http://maven.renci.org/NeuroBridge/neurobridge#PainFinding
14-19	2541-2542	,	_
14-20	2543-2546	and	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
14-21	2547-2555	Children	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
14-22	2556-2567	Nutritional	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
14-23	2568-2578	Supplement	http://maven.renci.org/NeuroBridge/neurobridge#FrustrationEmotionTaskforChildren
14-24	2579-2586	Program	_
14-25	2587-2588	(	_
14-26	2589-2592	WIC	_
14-27	2593-2594	)	_
14-28	2595-2602	Clinics	_
14-29	2603-2607	when	_
14-30	2608-2620	participants	_
14-31	2621-2625	were	_
14-32	2626-2630	6–17	_
14-33	2631-2637	months	_
14-34	2638-2641	old	_
14-35	2642-2643	.	_

15-1	2644-2656	Participants	_
15-2	2657-2666	completed	_
15-3	2667-2676	in-person	_
15-4	2677-2688	assessments	_
15-5	2689-2691	at	_
15-6	2692-2695	age	_
15-7	2696-2699	1.5	_
15-8	2700-2701	,	_
15-9	2702-2703	2	_
15-10	2704-2705	,	_
15-11	2706-2709	3.5	_
15-12	2710-2711	,	_
15-13	2712-2713	5	_
15-14	2714-2715	,	_
15-15	2716-2719	5.5	_
15-16	2720-2721	,	_
15-17	2722-2723	6	_
15-18	2724-2725	,	_
15-19	2726-2727	8	_
15-20	2728-2729	,	_
15-21	2730-2732	10	_
15-22	2733-2734	,	_
15-23	2735-2737	11	_
15-24	2738-2739	,	_
15-25	2740-2742	12	_
15-26	2743-2744	,	_
15-27	2745-2747	15	_
15-28	2748-2749	,	_
15-29	2750-2752	17	_
15-30	2753-2754	,	_
15-31	2755-2757	20	_
15-32	2758-2759	,	_
15-33	2760-2763	and	_
15-34	2764-2766	22	_
15-35	2767-2768	.	_

16-1	2769-2773	This	_
16-2	2774-2779	study	_
16-3	2780-2783	has	_
16-4	2784-2787	the	_
16-5	2788-2796	strength	_
16-6	2797-2799	of	_
16-7	2800-2808	allowing	_
16-8	2809-2812	for	_
16-9	2813-2823	concurrent	_
16-10	2824-2835	examination	_
16-11	2836-2838	of	_
16-12	2839-2842	the	_
16-13	2843-2851	relative	_
16-14	2852-2861	influence	_
16-15	2862-2864	of	_
16-16	2865-2875	adolescent	_
16-17	2876-2886	trajectory	_
16-18	2887-2889	of	_
16-19	2890-2898	cannabis	_
16-20	2899-2902	use	_
16-21	2903-2904	,	_
16-22	2905-2911	recent	_
16-23	2912-2921	frequency	_
16-24	2922-2924	of	_
16-25	2925-2928	use	_
16-26	2929-2930	,	_
16-27	2931-2934	and	_
16-28	2935-2938	age	_
16-29	2939-2941	of	_
16-30	2942-2947	onset	_
16-31	2948-2949	.	_

17-1	2950-2957	Because	_
17-2	2958-2966	subjects	_
17-3	2967-2971	were	_
17-4	2972-2981	recruited	_
17-5	2982-2984	in	_
17-6	2985-2992	infancy	_
17-7	2993-2996	and	_
17-8	2997-3005	followed	_
17-9	3006-3019	prospectively	_
17-10	3020-3021	,	_
17-11	3022-3024	it	_
17-12	3025-3028	was	_
17-13	3029-3032	not	_
17-14	3033-3041	possible	_
17-15	3042-3044	to	_
17-16	3045-3052	control	_
17-17	3053-3056	the	_
17-18	3057-3063	number	_
17-19	3064-3066	of	_
17-20	3067-3079	participants	_
17-21	3080-3084	that	_
17-22	3085-3090	would	_
17-23	3091-3101	ultimately	_
17-24	3102-3104	go	_
17-25	3105-3107	on	_
17-26	3108-3110	to	_
17-27	3111-3117	engage	_
17-28	3118-3120	in	_
17-29	3121-3129	cannabis	_
17-30	3130-3133	use	_
17-31	3134-3135	.	_

18-1	3136-3142	Rather	_
18-2	3143-3144	,	_
18-3	3145-3147	we	_
18-4	3148-3152	took	_
18-5	3153-3154	a	_
18-6	3155-3166	data-driven	_
18-7	3167-3175	approach	_
18-8	3176-3178	to	_
18-9	3179-3188	determine	_
18-10	3189-3192	the	_
18-11	3193-3202	different	_
18-12	3203-3215	trajectories	_
18-13	3216-3218	of	_
18-14	3219-3227	cannabis	_
18-15	3228-3231	use	_
18-16	3232-3236	that	_
18-17	3237-3241	were	_
18-18	3242-3249	present	_
18-19	3250-3255	among	_
18-20	3256-3260	PMCP	_
18-21	3261-3273	participants	_
18-22	3274-3275	,	_
18-23	3276-3279	and	_
18-24	3280-3282	to	_
18-25	3283-3286	use	_
18-26	3287-3292	these	_
18-27	3293-3303	trajectory	_
18-28	3304-3310	groups	_
18-29	3311-3313	as	_
18-30	3314-3317	the	_
18-31	3318-3323	basis	_
18-32	3324-3327	for	_
18-33	3328-3331	our	_
18-34	3332-3342	functional	_
18-35	3343-3355	connectivity	_
18-36	3356-3364	analyses	_
18-37	3365-3366	.	_

19-1	3367-3379	Participants	_
19-2	3380-3392	Participants	_
19-3	3393-3397	were	_
19-4	3398-3403	n=158	_
19-5	3404-3408	PMCP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-6	3409-3421	participants	_
19-7	3422-3425	who	_
19-8	3426-3435	completed	_
19-9	3436-3438	an	_
19-10	3439-3443	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-11	3444-3448	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
19-12	3449-3452	and	_
19-13	3453-3462	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
19-14	3463-3466	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
19-15	3467-3475	measures	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
19-16	3476-3478	at	_
19-17	3479-3482	age	_
19-18	3483-3485	20	_
19-19	3486-3487	.	_

20-1	3488-3491	All	_
20-2	3492-3500	subjects	_
20-3	3501-3505	were	_
20-4	3506-3514	eligible	_
20-5	3515-3517	to	_
20-6	3518-3529	participate	_
20-7	3530-3532	in	_
20-8	3533-3536	the	_
20-9	3537-3544	imaging	_
20-10	3545-3550	study	_
20-11	3551-3557	unless	_
20-12	3558-3562	they	_
20-13	3563-3571	reported	_
20-14	3572-3575	any	_
20-15	3576-3584	standard	_
20-16	3585-3588	MRI	_
20-17	3589-3606	contraindications	_
20-18	3607-3608	.	_

21-1	3609-3619	Procedures	_
21-2	3620-3624	were	_
21-3	3625-3633	approved	_
21-4	3634-3636	by	_
21-5	3637-3640	the	_
21-6	3641-3651	University	_
21-7	3652-3654	of	_
21-8	3655-3665	Pittsburgh	_
21-9	3666-3679	Institutional	_
21-10	3680-3686	Review	_
21-11	3687-3692	Board	_
21-12	3693-3694	.	_

22-1	3695-3698	All	_
22-2	3699-3711	participants	_
22-3	3712-3720	provided	_
22-4	3721-3728	written	_
22-5	3729-3737	informed	_
22-6	3738-3745	consent	_
22-7	3746-3748	to	_
22-8	3749-3754	study	_
22-9	3755-3765	procedures	_
22-10	3766-3769	and	_
22-11	3770-3774	were	_
22-12	3775-3786	compensated	_
22-13	3787-3790	for	_
22-14	3791-3796	their	_
22-15	3797-3810	participation	_
22-16	3811-3812	.	_

23-1	3813-3821	Measures	_
23-2	3822-3830	Cannabis	_
23-3	3831-3834	Use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
23-4	3835-3843	Cannabis	_
23-5	3844-3847	use	_
23-6	3848-3863	characteristics	_
23-7	3864-3868	were	_
23-8	3869-3877	assessed	_
23-9	3878-3880	at	_
23-10	3881-3884	age	_
23-11	3885-3887	20	_
23-12	3888-3893	using	_
23-13	3894-3897	the	_
23-14	3898-3906	Lifetime	_
23-15	3907-3914	History	_
23-16	3915-3917	of	_
23-17	3918-3922	Drug	_
23-18	3923-3926	Use	_
23-19	3927-3930	and	_
23-20	3931-3935	Drug	_
23-21	3936-3947	Consumption	_
23-22	3948-3949	,	_
23-23	3950-3951	a	_
23-24	3952-3968	psychometrically	_
23-25	3969-3974	sound	_
23-26	3975-3976	,	_
23-27	3977-3992	semi-structured	_
23-28	3993-4002	interview	_
23-29	4003-4004	.	_

24-1	4005-4009	This	_
24-2	4010-4013	was	_
24-3	4014-4017	the	_
24-4	4018-4023	first	_
24-5	4024-4029	visit	_
24-6	4030-4032	at	_
24-7	4033-4038	which	_
24-8	4039-4051	participants	_
24-9	4052-4056	were	_
24-10	4057-4062	asked	_
24-11	4063-4068	about	_
24-12	4069-4074	their	_
24-13	4075-4084	frequency	_
24-14	4085-4088	and	_
24-15	4089-4097	quantity	_
24-16	4098-4100	of	_
24-17	4101-4104	use	_
24-18	4105-4111	across	_
24-19	4112-4123	development	_
24-20	4124-4125	.	_

25-1	4126-4129	For	_
25-2	4130-4134	each	_
25-3	4135-4139	year	_
25-4	4140-4145	since	_
25-5	4146-4151	their	_
25-6	4152-4157	first	_
25-7	4158-4161	use	_
25-8	4162-4163	,	_
25-9	4164-4176	participants	_
25-10	4177-4185	reported	_
25-11	4186-4191	their	_
25-12	4192-4199	average	_
25-13	4200-4210	days/month	_
25-14	4211-4213	of	_
25-15	4214-4222	cannabis	_
25-16	4223-4226	use	_
25-17	4227-4228	,	_
25-18	4229-4236	average	_
25-19	4237-4245	quantity	_
25-20	4246-4247	,	_
25-21	4248-4255	maximum	_
25-22	4256-4264	quantity	_
25-23	4265-4266	,	_
25-24	4267-4270	and	_
25-25	4271-4278	maximum	_
25-26	4279-4285	number	_
25-27	4286-4288	of	_
25-28	4289-4293	days	_
25-29	4294-4299	using	_
25-30	4300-4305	their	_
25-31	4306-4313	maximum	_
25-32	4314-4322	quantity	_
25-33	4323-4325	of	_
25-34	4326-4334	cannabis	_
25-35	4335-4336	.	_

26-1	4337-4350	Retrospective	_
26-2	4351-4357	report	_
26-3	4358-4360	of	_
26-4	4361-4369	cannabis	_
26-5	4370-4373	use	_
26-6	4374-4376	is	_
26-7	4377-4382	valid	_
26-8	4383-4384	,	_
26-9	4385-4388	and	_
26-10	4389-4392	may	_
26-11	4393-4402	sometimes	_
26-12	4403-4405	be	_
26-13	4406-4410	more	_
26-14	4411-4419	accurate	_
26-15	4420-4424	than	_
26-16	4425-4435	concurrent	_
26-17	4436-4442	report	_
26-18	4443-4450	because	_
26-19	4451-4462	adolescents	_
26-20	4463-4466	may	_
26-21	4467-4479	under-report	_
26-22	4480-4485	their	_
26-23	4486-4493	current	_
26-24	4494-4497	use	_
26-25	4498-4505	because	_
26-26	4506-4508	of	_
26-27	4509-4517	concerns	_
26-28	4518-4523	about	_
26-29	4524-4529	legal	_
26-30	4530-4542	consequences	_
26-31	4543-4544	.	_

27-1	4545-4548	The	_
27-2	4549-4556	current	_
27-3	4557-4565	analyses	_
27-4	4566-4573	focused	_
27-5	4574-4576	on	_
27-6	4577-4584	average	_
27-7	4585-4594	frequency	_
27-8	4595-4597	of	_
27-9	4598-4601	use	_
27-10	4602-4605	for	_
27-11	4606-4610	each	_
27-12	4611-4615	year	_
27-13	4616-4619	and	_
27-14	4620-4623	age	_
27-15	4624-4626	of	_
27-16	4627-4637	initiation	_
27-17	4638-4639	.	_

28-1	4640-4647	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
28-2	4648-4651	Use	_
28-3	4652-4658	Annual	_
28-4	4659-4666	alcohol	_
28-5	4667-4670	use	_
28-6	4671-4680	frequency	_
28-7	4681-4682	(	_
28-8	4683-4693	days/month	_
28-9	4694-4695	)	_
28-10	4696-4699	and	_
28-11	4700-4708	quantity	_
28-12	4709-4710	(	_
28-13	4711-4718	average	_
28-14	4719-4725	number	_
28-15	4726-4728	of	_
28-16	4729-4744	drinks/occasion	_
28-17	4745-4746	)	_
28-18	4747-4750	for	_
28-19	4751-4755	each	_
28-20	4756-4760	year	_
28-21	4761-4766	since	_
28-22	4767-4779	participants	_
28-23	4780-4781	’	_
28-24	4782-4787	first	_
28-25	4788-4795	alcohol	_
28-26	4796-4799	use	_
28-27	4800-4804	were	_
28-28	4805-4813	assessed	_
28-29	4814-4816	at	_
28-30	4817-4820	age	_
28-31	4821-4823	20	_
28-32	4824-4829	using	_
28-33	4830-4833	the	_
28-34	4834-4842	Lifetime	_
28-35	4843-4851	Drinking	_
28-36	4852-4859	History	_
28-37	4860-4861	.	_

29-1	4862-4865	The	_
29-2	4866-4873	product	_
29-3	4874-4876	of	_
29-4	4877-4884	alcohol	_
29-5	4885-4888	use	_
29-6	4889-4898	frequency	_
29-7	4899-4902	and	_
29-8	4903-4911	quantity	_
29-9	4912-4915	was	_
29-10	4916-4926	calculated	_
29-11	4927-4930	for	_
29-12	4931-4935	each	_
29-13	4936-4940	year	_
29-14	4941-4944	and	_
29-15	4945-4952	average	_
29-16	4953-4960	alcohol	_
29-17	4961-4969	exposure	_
29-18	4970-4974	from	_
29-19	4975-4978	age	_
29-20	4979-4981	10	_
29-21	4982-4984	to	_
29-22	4985-4987	19	_
29-23	4988-4991	was	_
29-24	4992-5000	included	_
29-25	5001-5003	as	_
29-26	5004-5005	a	_
29-27	5006-5015	covariate	_
29-28	5016-5018	in	_
29-29	5019-5022	all	_
29-30	5023-5033	functional	_
29-31	5034-5046	connectivity	_
29-32	5047-5055	analyses	_
29-33	5056-5057	.	_

30-1	5058-5061	Age	_
30-2	5062-5064	22	_
30-3	5065-5077	Psychosocial	_
30-4	5078-5086	Outcomes	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
30-5	5087-5097	Depression	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
30-6	5098-5110	Participants	_
30-7	5111-5120	completed	_
30-8	5121-5124	the	_
30-9	5125-5129	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-10	5130-5140	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-11	5141-5150	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-12	5151-5152	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-13	5153-5156	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-14	5157-5158	;	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-15	5159-5161	44	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-16	5162-5163	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
30-17	5164-5166	at	_
30-18	5167-5170	age	_
30-19	5171-5173	20	_
30-20	5174-5177	and	_
30-21	5178-5180	22	_
30-22	5181-5182	,	_
30-23	5183-5184	a	_
30-24	5185-5191	widely	_
30-25	5192-5196	used	_
30-26	5197-5198	,	_
30-27	5199-5206	21-item	_
30-28	5207-5218	self-report	_
30-29	5219-5232	questionnaire	_
30-30	5233-5237	that	_
30-31	5238-5241	had	_
30-32	5242-5250	adequate	_
30-33	5251-5262	reliability	_
30-34	5263-5265	in	_
30-35	5266-5270	this	_
30-36	5271-5277	sample	_
30-37	5278-5279	(	_
30-38	5280-5285	α=.89	_
30-39	5286-5287	)	_
30-40	5288-5289	.	_

31-1	5290-5293	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
31-2	5294-5300	scores	_
31-3	5301-5304	did	_
31-4	5305-5308	not	_
31-5	5309-5315	change	_
31-6	5316-5329	significantly	_
31-7	5330-5334	from	_
31-8	5335-5338	age	_
31-9	5339-5341	20	_
31-10	5342-5344	to	_
31-11	5345-5347	22	_
31-12	5348-5349	(	_
31-13	5350-5351	F	_
31-14	5352-5353	(	_
31-15	5354-5359	302,1	_
31-16	5360-5361	)	_
31-17	5362-5367	=.803	_
31-18	5368-5369	,	_
31-19	5370-5376	p=.371	_
31-20	5377-5378	)	_
31-21	5379-5380	.	_

32-1	5381-5390	Anhedonia	_
32-2	5391-5393	At	_
32-3	5394-5397	age	_
32-4	5398-5400	22	_
32-5	5401-5405	only	_
32-6	5406-5407	,	_
32-7	5408-5420	participants	_
32-8	5421-5430	completed	_
32-9	5431-5434	the	_
32-10	5435-5450	Snaith-Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
32-11	5451-5459	Pleasure	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
32-12	5460-5465	Scale	http://maven.renci.org/NeuroBridge/neurobridge#HamiltonAnxietyRatingScale
32-13	5466-5467	,	_
32-14	5468-5469	a	_
32-15	5470-5486	psychometrically	_
32-16	5487-5492	sound	_
32-17	5493-5494	,	_
32-18	5495-5502	14-item	_
32-19	5503-5516	questionnaire	_
32-20	5517-5528	appropriate	_
32-21	5529-5532	for	_
32-22	5533-5542	measuring	_
32-23	5543-5552	anhedonia	_
32-24	5553-5555	in	_
32-25	5556-5563	typical	_
32-26	5564-5567	and	_
32-27	5568-5576	clinical	_
32-28	5577-5584	samples	_
32-29	5585-5586	.	_

33-1	5587-5598	Reliability	_
33-2	5599-5602	was	_
33-3	5603-5611	adequate	_
33-4	5612-5614	in	_
33-5	5615-5619	this	_
33-6	5620-5626	sample	_
33-7	5627-5628	(	_
33-8	5629-5635	α=.851	_
33-9	5636-5637	)	_
33-10	5638-5639	.	_

34-1	5640-5651	Educational	_
34-2	5652-5662	Attainment	_
34-3	5663-5675	Participants	_
34-4	5676-5684	reported	_
34-5	5685-5690	their	_
34-6	5691-5698	highest	_
34-7	5699-5704	level	_
34-8	5705-5707	of	_
34-9	5708-5714	school	_
34-10	5715-5724	completed	_
34-11	5725-5727	on	_
34-12	5728-5729	a	_
34-13	5730-5738	13-point	_
34-14	5739-5744	scale	_
34-15	5745-5746	(	_
34-16	5747-5748	“	_
34-17	5749-5754	below	_
34-18	5755-5760	grade	_
34-19	5761-5762	9	_
34-20	5763-5764	”	_
34-21	5765-5767	to	_
34-22	5768-5769	“	_
34-23	5770-5780	completion	_
34-24	5781-5783	of	_
34-25	5784-5792	graduate	_
34-26	5793-5799	degree	_
34-27	5800-5801	”	_
34-28	5802-5803	)	_
34-29	5804-5805	.	_

35-1	5806-5809	For	_
35-2	5810-5813	the	_
35-3	5814-5821	current	_
35-4	5822-5830	analyses	_
35-5	5831-5832	,	_
35-6	5833-5845	participants	_
35-7	5846-5850	were	_
35-8	5851-5861	classified	_
35-9	5862-5864	as	_
35-10	5865-5871	having	_
35-11	5872-5878	either	_
35-12	5879-5887	obtained	_
35-13	5888-5889	“	_
35-14	5890-5894	high	_
35-15	5895-5901	school	_
35-16	5902-5909	diploma	_
35-17	5910-5911	(	_
35-18	5912-5914	or	_
35-19	5915-5918	GED	_
35-20	5919-5920	)	_
35-21	5921-5923	or	_
35-22	5924-5928	less	_
35-23	5929-5930	”	_
35-24	5931-5933	or	_
35-25	5934-5935	“	_
35-26	5936-5940	some	_
35-27	5941-5947	higher	_
35-28	5948-5957	education	_
35-29	5958-5960	or	_
35-30	5961-5965	more	_
35-31	5966-5967	”	_
35-32	5968-5969	(	_
35-33	5970-5974	39.9	_
35-34	5975-5976	%	_
35-35	5977-5979	at	_
35-36	5980-5983	age	_
35-37	5984-5986	20	_
35-38	5987-5988	;	_
35-39	5989-5991	52	_
35-40	5992-5993	%	_
35-41	5994-5996	at	_
35-42	5997-5999	22	_
35-43	6000-6001	)	_
35-44	6002-6003	.	_

36-1	6004-6015	Educational	_
36-2	6016-6026	attainment	_
36-3	6027-6036	increased	_
36-4	6037-6041	from	_
36-5	6042-6045	age	_
36-6	6046-6048	20	_
36-7	6049-6051	to	_
36-8	6052-6055	age	_
36-9	6056-6058	22	_
36-10	6059-6060	(	_
36-11	6061-6069	X2=57.85	_
36-12	6070-6071	,	_
36-13	6072-6077	p=.00	_
36-14	6078-6079	)	_
36-15	6080-6081	.	_

37-1	6082-6092	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
37-2	6093-6105	Connectivity	_
37-3	6106-6114	Analysis	_
37-4	6115-6119	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-5	6120-6131	Acquisition	_
37-6	6132-6141	Procedure	_
37-7	6142-6154	Participants	_
37-8	6155-6156	(	_
37-9	6157-6162	n=186	_
37-10	6163-6164	)	_
37-11	6165-6174	underwent	_
37-12	6175-6185	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-13	6186-6193	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
37-14	6194-6196	on	_
37-15	6197-6198	a	_
37-16	6199-6206	Siemens	_
37-17	6207-6210	TIM	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
37-18	6211-6215	Trio	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
37-19	6216-6218	3T	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
37-20	6219-6226	scanner	http://maven.renci.org/NeuroBridge/neurobridge#ConnersRatingScaleRevised
37-21	6227-6232	using	_
37-22	6233-6234	a	_
37-23	6235-6243	gradient	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-24	6244-6248	echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-25	6249-6255	planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-26	6256-6263	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-27	6264-6265	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-28	6266-6269	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-29	6270-6271	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-30	6272-6280	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
37-31	6281-6285	with	_
37-32	6286-6288	34	_
37-33	6289-6294	axial	_
37-34	6295-6301	slices	_
37-35	6302-6303	(	_
37-36	6304-6309	3.1mm	_
37-37	6310-6315	thick	_
37-38	6316-6317	;	_
37-39	6318-6333	TR/TE=2000/28ms	_
37-40	6334-6335	,	_
37-41	6336-6344	FOV=20cm	_
37-42	6345-6346	,	_
37-43	6347-6359	matrix=64×64	_
37-44	6360-6361	)	_
37-45	6362-6363	,	_
37-46	6364-6366	as	_
37-47	6367-6375	reported	_
37-48	6376-6386	previously	_
37-49	6387-6388	.	_

38-1	6389-6390	A	_
38-2	6391-6400	reference	_
38-3	6401-6404	EPI	_
38-4	6405-6409	scan	_
38-5	6410-6413	was	_
38-6	6414-6422	acquired	_
38-7	6423-6426	and	_
38-8	6427-6436	inspected	_
38-9	6437-6440	for	_
38-10	6441-6450	artifacts	_
38-11	6451-6454	and	_
38-12	6455-6461	signal	_
38-13	6462-6463	.	_

39-1	6464-6476	Twenty-eight	_
39-2	6477-6489	participants	_
39-3	6490-6494	were	_
39-4	6495-6503	excluded	_
39-5	6504-6511	because	_
39-6	6512-6514	of	_
39-7	6515-6527	intoxication	_
39-8	6528-6529	(	_
39-9	6530-6533	n=4	_
39-10	6534-6535	)	_
39-11	6536-6537	,	_
39-12	6538-6547	psychosis	_
39-13	6548-6549	(	_
39-14	6550-6553	n=1	_
39-15	6554-6555	)	_
39-16	6556-6557	,	_
39-17	6558-6559	<	_
39-18	6560-6562	75	_
39-19	6563-6564	%	_
39-20	6565-6573	response	_
39-21	6574-6578	rate	_
39-22	6579-6580	(	_
39-23	6581-6585	n=13	_
39-24	6586-6587	)	_
39-25	6588-6589	,	_
39-26	6590-6594	poor	_
39-27	6595-6603	coverage	_
39-28	6604-6605	(	_
39-29	6606-6609	n=8	_
39-30	6610-6611	)	_
39-31	6612-6613	,	_
39-32	6614-6616	or	_
39-33	6617-6625	unusable	_
39-34	6626-6630	data	_
39-35	6631-6632	(	_
39-36	6633-6636	n=2	_
39-37	6637-6638	)	_
39-38	6639-6640	,	_
39-39	6641-6650	resulting	_
39-40	6651-6653	in	_
39-41	6654-6657	the	_
39-42	6658-6663	final	_
39-43	6664-6670	sample	_
39-44	6671-6673	of	_
39-45	6674-6679	n=158	_
39-46	6680-6688	included	_
39-47	6689-6691	in	_
39-48	6692-6695	the	_
39-49	6696-6703	current	_
39-50	6704-6712	analyses	_
39-51	6713-6714	.	_

40-1	6715-6718	All	_
40-2	6719-6731	participants	_
40-3	6732-6735	had	_
40-4	6736-6737	<	_
40-5	6738-6741	2mm	_
40-6	6742-6746	mean	_
40-7	6747-6755	movement	_
40-8	6756-6758	in	_
40-9	6759-6762	any	_
40-10	6763-6772	direction	_
40-11	6773-6774	.	_

41-1	6775-6778	The	_
41-2	6779-6783	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
41-3	6784-6792	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
41-4	6793-6796	was	_
41-5	6797-6799	an	_
41-6	6800-6805	8-min	_
41-7	6806-6807	,	_
41-8	6808-6816	24-trial	_
41-9	6817-6818	,	_
41-10	6819-6823	slow	_
41-11	6824-6837	event-related	_
41-12	6838-6851	card-guessing	_
41-13	6852-6856	game	_
41-14	6857-6861	that	_
41-15	6862-6870	assesses	_
41-16	6871-6879	response	_
41-17	6880-6882	to	_
41-18	6883-6895	anticipation	_
41-19	6896-6899	and	_
41-20	6900-6907	receipt	_
41-21	6908-6910	of	_
41-22	6911-6919	monetary	_
41-23	6920-6926	reward	_
41-24	6927-6928	(	_
41-25	6929-6932	see	_
41-26	6933-6936	for	_
41-27	6937-6941	task	_
41-28	6942-6949	details	_
41-29	6950-6951	)	_
41-30	6952-6953	.	_

42-1	6954-6966	Participants	_
42-2	6967-6974	guessed	_
42-3	6975-6982	whether	_
42-4	6983-6984	a	_
42-5	6985-6989	card	_
42-6	6990-6993	was	_
42-7	6994-6998	high	_
42-8	6999-7001	or	_
42-9	7002-7005	low	_
42-10	7006-7007	,	_
42-11	7008-7019	anticipated	_
42-12	7020-7023	win	_
42-13	7024-7026	or	_
42-14	7027-7031	loss	_
42-15	7032-7033	,	_
42-16	7034-7037	and	_
42-17	7038-7046	received	_
42-18	7047-7055	feedback	_
42-19	7056-7059	and	_
42-20	7060-7068	monetary	_
42-21	7069-7076	outcome	_
42-22	7077-7078	.	_

43-1	7079-7085	Trials	_
43-2	7086-7090	were	_
43-3	7091-7100	presented	_
43-4	7101-7103	in	_
43-5	7104-7105	a	_
43-6	7106-7111	fixed	_
43-7	7112-7113	,	_
43-8	7114-7126	pseudorandom	_
43-9	7127-7132	order	_
43-10	7133-7134	,	_
43-11	7135-7139	with	_
43-12	7140-7152	participants	_
43-13	7153-7160	unaware	_
43-14	7161-7163	of	_
43-15	7164-7169	fixed	_
43-16	7170-7178	outcomes	_
43-17	7179-7180	.	_

44-1	7181-7185	This	_
44-2	7186-7190	task	_
44-3	7191-7199	robustly	_
44-4	7200-7209	activates	_
44-5	7210-7216	reward	_
44-6	7217-7226	circuitry	_
44-7	7227-7228	,	_
44-8	7229-7238	including	_
44-9	7239-7242	the	_
44-10	7243-7247	NAcc	_
44-11	7248-7249	(	_
44-12	7250-7253	see	_
44-13	7254-7266	Supplemental	_
44-14	7267-7273	Figure	_
44-15	7274-7275	1	_
44-16	7276-7279	for	_
44-17	7280-7284	task	_
44-18	7285-7289	main	_
44-19	7290-7297	effects	_
44-20	7298-7299	)	_
44-21	7300-7301	.	_

45-1	7302-7306	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
45-2	7307-7317	Functional	_
45-3	7318-7330	Connectivity	_
45-4	7331-7339	Analysis	_
45-5	7340-7342	We	_
45-6	7343-7352	conducted	_
45-7	7353-7366	preprocessing	_
45-8	7367-7370	and	_
45-9	7371-7379	analysis	_
45-10	7380-7385	using	_
45-11	7386-7390	SPM8	_
45-12	7391-7392	(	_
45-13	7393-7397	http	_
45-14	7398-7399	:	_
45-15	7400-7427	//www.fil.ion.ucl.ac.uk/spm	_
45-16	7428-7429	)	_
45-17	7430-7431	.	_

46-1	7432-7439	Imaging	_
46-2	7440-7444	data	_
46-3	7445-7449	were	_
46-4	7450-7459	realigned	_
46-5	7460-7461	,	_
46-6	7462-7470	unwarped	_
46-7	7471-7472	,	_
46-8	7473-7486	co-registered	_
46-9	7487-7489	to	_
46-10	7490-7499	segmented	_
46-11	7500-7510	structural	_
46-12	7511-7517	images	_
46-13	7518-7519	,	_
46-14	7520-7529	spatially	_
46-15	7530-7540	normalized	_
46-16	7541-7545	into	_
46-17	7546-7554	standard	_
46-18	7555-7567	stereotactic	_
46-19	7568-7573	space	_
46-20	7574-7575	(	_
46-21	7576-7584	Montreal	_
46-22	7585-7597	Neurological	_
46-23	7598-7607	Institute	_
46-24	7608-7609	)	_
46-25	7610-7615	using	_
46-26	7616-7617	a	_
46-27	7618-7630	12-parameter	_
46-28	7631-7637	affine	_
46-29	7638-7643	model	_
46-30	7644-7645	,	_
46-31	7646-7649	and	_
46-32	7650-7658	smoothed	_
46-33	7659-7663	with	_
46-34	7664-7665	a	_
46-35	7666-7669	6mm	_
46-36	7670-7674	FWHM	_
46-37	7675-7683	Gaussian	_
46-38	7684-7690	filter	_
46-39	7691-7692	.	_

47-1	7693-7703	Voxel-wise	_
47-2	7704-7710	signal	_
47-3	7711-7722	intensities	_
47-4	7723-7727	were	_
47-5	7728-7733	ratio	_
47-6	7734-7744	normalized	_
47-7	7745-7747	to	_
47-8	7748-7751	the	_
47-9	7752-7763	whole-brain	_
47-10	7764-7770	global	_
47-11	7771-7775	mean	_
47-12	7776-7777	.	_

48-1	7778-7788	Functional	_
48-2	7789-7801	connectivity	_
48-3	7802-7810	analyses	_
48-4	7811-7813	of	_
48-5	7814-7817	win	_
48-6	7818-7830	anticipation	_
48-7	7831-7832	>	_
48-8	7833-7837	loss	_
48-9	7838-7850	anticipation	_
48-10	7851-7854	and	_
48-11	7855-7858	win	_
48-12	7859-7866	outcome	_
48-13	7867-7868	>	_
48-14	7869-7873	loss	_
48-15	7874-7881	outcome	_
48-16	7882-7886	were	_
48-17	7887-7896	conducted	_
48-18	7897-7902	using	_
48-19	7903-7922	psychophysiological	_
48-20	7923-7934	interaction	_
48-21	7935-7936	(	_
48-22	7937-7941	gPPI	_
48-23	7942-7943	)	_
48-24	7944-7945	(	_
48-25	7946-7949	for	_
48-26	7950-7961	description	_
48-27	7962-7964	of	_
48-28	7965-7968	PPI	_
48-29	7969-7970	,	_
48-30	7971-7977	please	_
48-31	7978-7981	see	_
48-32	7982-7983	)	_
48-33	7984-7985	.	_

49-1	7986-7991	These	_
49-2	7992-8001	contrasts	_
49-3	8002-8006	were	_
49-4	8007-8013	chosen	_
49-5	8014-8021	because	_
49-6	8022-8025	PPI	_
49-7	8026-8034	analyses	_
49-8	8035-8042	require	_
49-9	8043-8046	the	_
49-10	8047-8055	contrast	_
49-11	8056-8058	of	_
49-12	8059-8060	2	_
49-13	8061-8067	active	_
49-14	8068-8072	task	_
49-15	8073-8083	conditions	_
49-16	8084-8085	(	_
49-17	8086-8092	rather	_
49-18	8093-8097	than	_
49-19	8098-8099	1	_
49-20	8100-8106	active	_
49-21	8107-8116	condition	_
49-22	8117-8120	and	_
49-23	8121-8122	1	_
49-24	8123-8131	baseline	_
49-25	8132-8141	condition	_
49-26	8142-8143	)	_
49-27	8144-8145	.	_

50-1	8146-8149	The	_
50-2	8150-8159	bilateral	_
50-3	8160-8164	NAcc	_
50-4	8165-8166	,	_
50-5	8167-8174	defined	_
50-6	8175-8187	anatomically	_
50-7	8188-8193	using	_
50-8	8194-8197	WFU	_
50-9	8198-8207	PickAtlas	_
50-10	8208-8209	(	_
50-11	8210-8212	v.	_
50-12	8213-8218	3.0.4	_
50-13	8219-8220	)	_
50-14	8221-8222	,	_
50-15	8223-8226	was	_
50-16	8227-8230	the	_
50-17	8231-8235	seed	_
50-18	8236-8242	region	_
50-19	8243-8250	because	_
50-20	8251-8253	of	_
50-21	8254-8257	its	_
50-22	8258-8266	critical	_
50-23	8267-8271	role	_
50-24	8272-8274	in	_
50-25	8275-8281	reward	_
50-26	8282-8292	processing	_
50-27	8293-8296	and	_
50-28	8297-8308	association	_
50-29	8309-8313	with	_
50-30	8314-8323	substance	_
50-31	8324-8327	use	_
50-32	8328-8329	.	_

51-1	8330-8340	Functional	_
51-2	8341-8353	connectivity	_
51-3	8354-8357	was	_
51-4	8358-8366	examined	_
51-5	8367-8374	between	_
51-6	8375-8378	the	_
51-7	8379-8383	NAcc	_
51-8	8384-8387	and	_
51-9	8388-8389	a	_
51-10	8390-8396	region	_
51-11	8397-8399	of	_
51-12	8400-8408	interest	_
51-13	8409-8418	including	_
51-14	8419-8422	the	_
51-15	8423-8426	PFC	_
51-16	8427-8430	and	_
51-17	8431-8434	ACC	_
51-18	8435-8436	,	_
51-19	8437-8444	defined	_
51-20	8445-8457	anatomically	_
51-21	8458-8463	using	_
51-22	8464-8467	WFU	_
51-23	8468-8477	PickAtlas	_
51-24	8478-8479	(	_
51-25	8480-8482	v.	_
51-26	8483-8488	3.0.4	_
51-27	8489-8490	)	_
51-28	8491-8493	to	_
51-29	8494-8501	include	_
51-30	8502-8510	Brodmann	_
51-31	8511-8516	Areas	_
51-32	8517-8521	9–12	_
51-33	8522-8523	,	_
51-34	8524-8529	24–25	_
51-35	8530-8531	,	_
51-36	8532-8537	32–33	_
51-37	8538-8539	,	_
51-38	8540-8543	and	_
51-39	8544-8549	44–47	_
51-40	8550-8551	(	_
51-41	8552-8555	see	_
51-42	8556-8568	supplemental	_
51-43	8569-8575	Figure	_
51-44	8576-8577	2	_
51-45	8578-8579	)	_
51-46	8580-8581	.	_

52-1	8582-8586	Data	_
52-2	8587-8595	Analyses	_
52-3	8596-8599	Aim	_
52-4	8600-8601	1	_
52-5	8602-8603	:	_
52-6	8604-8617	Developmental	_
52-7	8618-8628	Trajectory	_
52-8	8629-8631	of	_
52-9	8632-8642	Adolescent	_
52-10	8643-8651	Cannabis	_
52-11	8652-8655	Use	_
52-12	8656-8666	Trajectory	_
52-13	8667-8672	group	_
52-14	8673-8681	analyses	_
52-15	8682-8686	used	_
52-16	8687-8696	frequency	_
52-17	8697-8699	of	_
52-18	8700-8708	cannabis	_
52-19	8709-8712	use	_
52-20	8713-8717	from	_
52-21	8718-8721	age	_
52-22	8722-8727	14–19	_
52-23	8728-8733	years	_
52-24	8734-8735	.	_

53-1	8736-8740	This	_
53-2	8741-8746	range	_
53-3	8747-8753	covers	_
53-4	8754-8755	a	_
53-5	8756-8761	large	_
53-6	8762-8769	portion	_
53-7	8770-8772	of	_
53-8	8773-8784	adolescence	_
53-9	8785-8786	,	_
53-10	8787-8795	includes	_
53-11	8796-8799	the	_
53-12	8800-8807	typical	_
53-13	8808-8811	age	_
53-14	8812-8814	of	_
53-15	8815-8825	initiation	_
53-16	8826-8827	,	_
53-17	8828-8831	and	_
53-18	8832-8840	included	_
53-19	8841-8850	past-year	_
53-20	8851-8854	use	_
53-21	8855-8862	because	_
53-22	8863-8874	assessments	_
53-23	8875-8883	occurred	_
53-24	8884-8886	on	_
53-25	8887-8889	or	_
53-26	8890-8896	around	_
53-27	8897-8909	participants	_
53-28	8910-8911	’	_
53-29	8912-8916	20th	_
53-30	8917-8926	birthdays	_
53-31	8927-8928	.	_

54-1	8929-8931	We	_
54-2	8932-8936	used	_
54-3	8937-8938	a	_
54-4	8939-8945	latent	_
54-5	8946-8951	class	_
54-6	8952-8958	growth	_
54-7	8959-8967	analyses	_
54-8	8968-8970	in	_
54-9	8971-8976	MPlus	_
54-10	8977-8978	,	_
54-11	8979-8984	which	_
54-12	8985-8995	identifies	_
54-13	8996-9004	clusters	_
54-14	9005-9007	of	_
54-15	9008-9014	people	_
54-16	9015-9017	in	_
54-17	9018-9024	common	_
54-18	9025-9038	developmental	_
54-19	9039-9047	pathways	_
54-20	9048-9049	.	_

55-1	9050-9056	Models	_
55-2	9057-9061	with	_
55-3	9062-9065	1–4	_
55-4	9066-9072	groups	_
55-5	9073-9077	were	_
55-6	9078-9084	tested	_
55-7	9085-9086	(	_
55-8	9087-9100	Supplementary	_
55-9	9101-9106	Table	_
55-10	9107-9108	1	_
55-11	9109-9110	)	_
55-12	9111-9112	.	_

56-1	9113-9115	We	_
56-2	9116-9124	followed	_
56-3	9125-9140	recommendations	_
56-4	9141-9145	that	_
56-5	9146-9149	the	_
56-6	9150-9158	smallest	_
56-7	9159-9164	group	_
56-8	9165-9172	contain	_
56-9	9173-9175	at	_
56-10	9176-9181	least	_
56-11	9182-9183	5	_
56-12	9184-9185	%	_
56-13	9186-9188	of	_
56-14	9189-9192	the	_
56-15	9193-9199	sample	_
56-16	9200-9201	.	_

57-1	9202-9205	Aim	_
57-2	9206-9207	2	_
57-3	9208-9209	:	_
57-4	9210-9219	Influence	_
57-5	9220-9222	of	_
57-6	9223-9231	Cannabis	_
57-7	9232-9235	Use	_
57-8	9236-9251	Characteristics	_
57-9	9252-9254	on	_
57-10	9255-9258	Age	_
57-11	9259-9261	20	_
57-12	9262-9272	Functional	_
57-13	9273-9285	Connectivity	_
57-14	9286-9293	One-way	_
57-15	9294-9299	ANOVA	_
57-16	9300-9303	was	_
57-17	9304-9308	used	_
57-18	9309-9311	to	_
57-19	9312-9316	test	_
57-20	9317-9320	the	_
57-21	9321-9327	effect	_
57-22	9328-9330	of	_
57-23	9331-9341	trajectory	_
57-24	9342-9347	group	_
57-25	9348-9350	on	_
57-26	9351-9355	NAcc	_
57-27	9356-9366	functional	_
57-28	9367-9379	connectivity	_
57-29	9380-9381	.	_

58-1	9382-9390	Clusters	_
58-2	9391-9404	demonstrating	_
58-3	9405-9416	significant	_
58-4	9417-9424	effects	_
58-5	9425-9427	of	_
58-6	9428-9438	trajectory	_
58-7	9439-9444	group	_
58-8	9445-9449	were	_
58-9	9450-9454	used	_
58-10	9455-9457	as	_
58-11	9458-9459	a	_
58-12	9460-9464	mask	_
58-13	9465-9468	for	_
58-14	9469-9477	post-hoc	_
58-15	9478-9486	pairwise	_
58-16	9487-9494	t-tests	_
58-17	9495-9496	.	_

59-1	9497-9507	Regression	_
59-2	9508-9511	was	_
59-3	9512-9516	used	_
59-4	9517-9519	to	_
59-5	9520-9524	test	_
59-6	9525-9528	the	_
59-7	9529-9535	effect	_
59-8	9536-9538	of	_
59-9	9539-9545	recent	_
59-10	9546-9555	frequency	_
59-11	9556-9558	of	_
59-12	9559-9567	cannabis	_
59-13	9568-9571	use	_
59-14	9572-9575	and	_
59-15	9576-9579	age	_
59-16	9580-9582	of	_
59-17	9583-9593	initiation	_
59-18	9594-9596	on	_
59-19	9597-9601	NAcc	_
59-20	9602-9612	functional	_
59-21	9613-9625	connectivity	_
59-22	9626-9627	.	_

60-1	9628-9633	Daily	_
60-2	9634-9642	nicotine	_
60-3	9643-9646	use	_
60-4	9647-9648	,	_
60-5	9649-9659	antisocial	_
60-6	9660-9671	personality	_
60-7	9672-9680	disorder	_
60-8	9681-9682	(	_
60-9	9683-9697	present/absent	_
60-10	9698-9699	)	_
60-11	9700-9701	,	_
60-12	9702-9710	lifetime	_
60-13	9711-9718	alcohol	_
60-14	9719-9727	exposure	_
60-15	9728-9729	,	_
60-16	9730-9733	and	_
60-17	9734-9737	SES	_
60-18	9738-9742	were	_
60-19	9743-9753	covariates	_
60-20	9754-9761	because	_
60-21	9762-9764	of	_
60-22	9765-9770	their	_
60-23	9771-9780	influence	_
60-24	9781-9783	on	_
60-25	9784-9790	reward	_
60-26	9791-9800	circuitry	_
60-27	9801-9803	or	_
60-28	9804-9815	association	_
60-29	9816-9820	with	_
60-30	9821-9831	trajectory	_
60-31	9832-9837	group	_
60-32	9838-9839	.	_

61-1	9840-9850	Functional	_
61-2	9851-9863	connectivity	_
61-3	9864-9868	with	_
61-4	9869-9872	the	_
61-5	9873-9876	PFC	_
61-6	9877-9880	was	_
61-7	9881-9887	tested	_
61-8	9888-9890	at	_
61-9	9891-9892	p	_
61-10	9893-9894	<	_
61-11	9895-9899	.005	_
61-12	9900-9903	and	_
61-13	9904-9914	correction	_
61-14	9915-9918	for	_
61-15	9919-9927	multiple	_
61-16	9928-9939	comparisons	_
61-17	9940-9944	used	_
61-18	9945-9946	a	_
61-19	9947-9960	cluster-level	_
61-20	9961-9974	FWE-corrected	_
61-21	9975-9976	p	_
61-22	9977-9978	<	_
61-23	9979-9982	.05	_
61-24	9983-9992	threshold	_
61-25	9993-9994	.	_

62-1	9995-9999	This	_
62-2	10000-10009	threshold	_
62-3	10010-10013	was	_
62-4	10014-10022	selected	_
62-5	10023-10025	to	_
62-6	10026-10033	balance	_
62-7	10034-10038	risk	_
62-8	10039-10042	for	_
62-9	10043-10047	Type	_
62-10	10048-10049	I	_
62-11	10050-10053	and	_
62-12	10054-10058	Type	_
62-13	10059-10061	II	_
62-14	10062-10067	error	_
62-15	10068-10069	,	_
62-16	10070-10075	based	_
62-17	10076-10078	on	_
62-18	10079-10086	current	_
62-19	10087-10102	recommendations	_
62-20	10103-10105	in	_
62-21	10106-10109	the	_
62-22	10110-10115	field	_
62-23	10116-10117	.	_

63-1	10118-10124	Carter	_
63-2	10125-10127	et	_
63-3	10128-10130	al	_
63-4	10131-10132	.	_

64-1	10133-10143	calculated	_
64-2	10144-10149	power	_
64-3	10150-10156	curves	_
64-4	10157-10159	to	_
64-5	10160-10170	illustrate	_
64-6	10171-10177	sample	_
64-7	10178-10183	sizes	_
64-8	10184-10193	necessary	_
64-9	10194-10196	to	_
64-10	10197-10203	detect	_
64-11	10204-10212	moderate	_
64-12	10213-10220	effects	_
64-13	10221-10223	at	_
64-14	10224-10231	various	_
64-15	10232-10243	statistical	_
64-16	10244-10254	thresholds	_
64-17	10255-10256	.	_

65-1	10257-10262	Based	_
65-2	10263-10265	on	_
65-3	10266-10271	their	_
65-4	10272-10284	calculations	_
65-5	10285-10286	,	_
65-6	10287-10288	a	_
65-7	10289-10298	threshold	_
65-8	10299-10301	of	_
65-9	10302-10303	p	_
65-10	10304-10305	<	_
65-11	10306-10310	.001	_
65-12	10311-10316	would	_
65-13	10317-10319	be	_
65-14	10320-10326	likely	_
65-15	10327-10329	to	_
65-16	10330-10337	obscure	_
65-17	10338-10348	meaningful	_
65-18	10349-10356	effects	_
65-19	10357-10359	in	_
65-20	10360-10362	on	_
65-21	10363-10366	our	_
65-22	10367-10374	current	_
65-23	10375-10381	sample	_
65-24	10382-10386	size	_
65-25	10387-10388	,	_
65-26	10389-10396	whereas	_
65-27	10397-10398	a	_
65-28	10399-10408	threshold	_
65-29	10409-10411	of	_
65-30	10412-10413	p	_
65-31	10414-10415	<	_
65-32	10416-10420	.005	_
65-33	10421-10426	would	_
65-34	10427-10432	allow	_
65-35	10433-10435	us	_
65-36	10436-10438	to	_
65-37	10439-10445	detect	_
65-38	10446-10447	a	_
65-39	10448-10456	moderate	_
65-40	10457-10463	effect	_
65-41	10464-10465	.	_

66-1	10466-10469	Aim	_
66-2	10470-10471	3	_
66-3	10472-10473	:	_
66-4	10474-10482	Relation	_
66-5	10483-10490	between	_
66-6	10491-10494	Age	_
66-7	10495-10497	20	_
66-8	10498-10508	Functional	_
66-9	10509-10521	Connectivity	_
66-10	10522-10525	and	_
66-11	10526-10529	Age	_
66-12	10530-10532	22	_
66-13	10533-10545	Psychosocial	_
66-14	10546-10554	Outcomes	_
66-15	10555-10562	Pearson	_
66-16	10563-10572	bivariate	_
66-17	10573-10584	correlation	_
66-18	10585-10593	analyses	_
66-19	10594-10600	tested	_
66-20	10601-10608	whether	_
66-21	10609-10619	functional	_
66-22	10620-10632	connectivity	_
66-23	10633-10640	related	_
66-24	10641-10643	to	_
66-25	10644-10654	adolescent	_
66-26	10655-10663	cannabis	_
66-27	10664-10667	use	_
66-28	10668-10671	was	_
66-29	10672-10682	associated	_
66-30	10683-10687	with	_
66-31	10688-10698	depression	_
66-32	10699-10700	,	_
66-33	10701-10710	anhedonia	_
66-34	10711-10712	,	_
66-35	10713-10715	or	_
66-36	10716-10727	educational	_
66-37	10728-10738	attainment	_
66-38	10739-10741	at	_
66-39	10742-10745	age	_
66-40	10746-10748	22	_
66-41	10749-10750	.	_

